Catch up on Myeloma2018 webcasts now!

The Myeloma2018 meeting was held in San Diego, on 7-9 September. The meeting provided an opportunity for leading experts in multiple myeloma (MM) to present and discuss the latest data and advancements in the field.

Treatment regimens for MM have continued to improve in recent years, as a result of extensive research in the field, leading to further developments in novel drug targets, drug combinations and biomarkers, all of which were featured during the Myeloma2018 meeting!
Clinical genetics, measurable residual disease (MRD), immunotherapy and drug resistance were also among the topics thoroughly discussed by the delegates. VJHemOnc are pleased to share exclusive, on-demand webcast presentations from the meeting.

Watch all of our webcasts here to stay up-to-date on current advances in myeloma presented at Myeloma2018.

Session I: Clinical Genomics

Featuring: Dr Ola Landgren
Memorial Sloan Kettering Cancer Center, New York City, NY
V(D)J Based MRD Tracking: the MSKCC Experience

Further reading
Session II: Genomics 2018 – What Have We Learned

Featuring: Dr Yuan Xiao Zhu
Mayo Clinic, Scottsdale, AZ
FAM46C and Multiple Myeloma

Further reading
Session III: Epigenetics

Featuring: Dr Constantine Mitsiades
Dana-Farber Cancer Institute, Boston, MA
Defining Mechanisms of Resistance and Novel Therapeutic Targets Through CRISPR-based Studies

Further reading
Session IV: Novel Targets

Featuring: Dr Keith Stewart
Mayo Clinic, Rochester, MN
PIKfyve in Myeloma

Further reading
Session V: Progression of MGUS-SMM-MM

Featuring: Dr Elisabet Manasanch
MD Anderson Cancer Center, Houston, TX
Clinical Insights in the Progression to Multiple Myeloma

Further reading
Session VI: Microenvironment

Featuring: Dr Bruno Paiva
University of Navarra, Pamplona, Spain
Immune Microenvironment

Further reading
Session VII: Genomics of Drug Resistance

Featuring: Dr Anja Seckinger
University of Heidelberg, Heidelberg, Germany
CD38 Sensitivity and (Upfront) Resistance

Further reading
Session VIII: Immunotherapy of Myeloma – T Cell Engagement

Featuring: Dr Yi Lin
Mayo Clinic, Rochester, MN
Industry BCMA CAR T-cell Trials

Further reading